Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets.

ABSTRACT: Breast cancer vaccines composed of antigens identified by serological analysis of cDNA expression libraries (SEREX) induce antigen specific immune responses in patients but have had disappointing clinical benefits. While many attempts to modify the adjuvants and vaccine method have been tried, one issue not addressed was whether the SEREX tumor-associated antigens identified from late stages of disease were ideal targets. We questioned in the transgenic TgMMTV-neu mouse model whether the antigen repertoire is distinct between early and late stage breast cancer and whether the antigens identified via SEREX from transgenic mice with early or late stage tumors would elicit differential anti-tumor effects to address this question. Three early stage antigens, Pdhx, Stk39, and Otud6B, were ident

SUBMITTER: Stanton SE 

PROVIDER: S-EPMC7087478 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature